LIVN logo

LivaNova PLC (LIVN)

$91.92

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on LIVN

Market cap

$5.06B

EPS

3.01

P/E ratio

22.5

Price to sales

2.86

Dividend yield

--

Beta

0.912344

Price on LIVN

Previous close

$92.44

Today's open

$92.73

Day's range

$91.63 - $93.64

52 week range

$52.37 - $99.38

Profile about LIVN

CEO

Vladimir Makatsaria

Employees

3300

Headquarters

Gloucester,

Exchange

Nasdaq Global Select

Shares outstanding

55086809

Issue type

Common Stock

LIVN industries and sectors

Healthcare

Medical Equipment & Supplies

News on LIVN

LivaNova: Paying Off The Last Legacy Bill Just As The Sleep Apnea Market Opens Up

LivaNova PLC is rapidly transitioning into a 'clean compounder' with strong growth prospects and legacy liabilities nearly resolved. LIVN raised 2026 guidance to 9-10% revenue growth and 14% adjusted EPS growth, driven by cardiopulmonary and neuromodulation segments. Oxygenator demand exceeds supply, with LIVN gaining market share and expanding production capacity, while OSA entry is poised for favorable reimbursement tailwinds.

news source

Seeking Alpha • Nov 12, 2026

news preview

LivaNova PLC (LIVN) Presents at 2026 UBS Global Healthcare Conference Transcript

LivaNova PLC ( LIVN ) 2026 UBS Global Healthcare Conference November 9, 2026 11:00 AM EST Company Participants Alex Shvartsburg - Chief Financial Officer Philip Kowalczyk - Chief Strategy & Corporate Development Officer Conference Call Participants Benjamin Bible Presentation Benjamin Bible Welcome. With me today is Alex Shvartsburg and Philip Kowalczyk, CFO and Head of Strategy and EVP from LivaNova.

news source

Seeking Alpha • Nov 9, 2026

news preview

LivaNova Q3 Earnings Call Highlights

LivaNova NASDAQ: LIVN reported third-quarter 2026 revenue growth of 10% from the prior-year period, driven by double-digit gains in its Cardiopulmonary and epilepsy businesses. The medical technology company raised its full-year revenue and adjusted earnings outlook, citing commercial execution, healthy demand and progress in manufacturing capacity expansion.

news source

MarketBeat • Nov 4, 2026

news preview

LivaNova PLC (LIVN) Q3 2026 Earnings Call Transcript

LivaNova PLC (LIVN) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 4, 2026

news preview

LivaNova Reports Third-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

GLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the third quarter ended September 30, 2026 and raised full-year 2026 guidance. Financial Summary and Highlights(1) Third-quarter revenue of $393.1 million increased 9.9% on a reported basis and 10.0% on a constant-currency basis as compared to the prior-year period Third-quarter U.S. GAAP diluted earnings per share of $0.11 and adjusted diluted earnings per.

news source

Business Wire • Nov 4, 2026

news preview

LivaNova (LIVN) Surpasses Q3 Earnings and Revenue Estimates

LivaNova (LIVN) came out with quarterly earnings of $1.23 per share, beating the Zacks Consensus Estimate of $1.03 per share. This compares to earnings of $1.11 per share a year ago.

news source

Zacks Investment Research • Nov 4, 2026

news preview

LivaNova (LIVN) Reports Q3 Earnings: What Key Metrics Have to Say

The headline numbers for LivaNova (LIVN) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

news source

Zacks Investment Research • Nov 4, 2026

news preview

Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova's VNS Therapy for Drug-Resistant Epilepsy

GLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Neuromodulation: Technology at the Neural Interface has published the full 36-month results from the CORE-VNS study, the first long-term effectiveness evaluation of contemporary VNS Therapy™ devices in people with Drug-Resistant Epilepsy (DRE). The article, “CORE-VNS Seizure and Non-Seizure 36 Month Outcomes in People with Drug-resistant Epilepsy,”1 re.

news source

Business Wire • Oct 23, 2026

news preview

LivaNova to Present at UBS, Wolfe, Stifel, and Jefferies Healthcare Conferences in November

GLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that members of the Company's Executive Leadership Team will provide general business updates during fireside chats at the four following November healthcare conferences: UBS Global Healthcare Conference on Mon., Nov. 9, from 11-11:35 a.m. EST in Palm Beach, Fla. 8th Annual Wolfe Research Healthcare Conference on Tues., Nov. 10, from 9:20-9:50 a.m. EST in New York City.

news source

Business Wire • Oct 21, 2026

news preview

LivaNova to Announce Third-Quarter 2026 Results

GLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2026 results on Wed., Nov. 4, 2026, at 1 p.m. Greenwich Mean Time (8 a.m. Eastern Standard Time). The Company will release its third-quarter 2026 results prior to the call.The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the.

news source

Business Wire • Sep 23, 2026

news preview

¹ Disclosures

Get started with M1

Invest in LivaNova PLC

Open an M1 investment account to buy and sell LivaNova PLC commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in LIVN on M1